Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition
This article was originally published in The Pink Sheet Daily
While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.
You may also be interested in...
All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.
Medivation continues its pipeline expansion efforts beyond Xtandi by paying $410m up front for a Phase III PARP inhibitor from BioMarin. Novo Nordisk acquires a pair of diabetes-focused start-ups, while Immatics will establish a US subsidiary on the MD Anderson Cancer Center campus in Houston.
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.